In acid-peptic disorder patients having Helicobacter pylori (H. pylori) infection, rabeprazole has comparable H. pylori elimination rates in comparison with omeprazole when co-administered with the antibiotics like clarithromycin and amoxicillin for about two weeks. 

A study was carried to investigate the efficacy of rabeprazole (20 mg) vs. omeprazole (40 mg) in the triple therapy regimen.

Overall, 100 H.pylori-infected patients who gave their consent for trial participation were incorporated. In total, 50 subjects were given omeprazole-based triple treatment and the other 50 subjects were given rabeprazole-based triple treatment. Following two weeks of triple therapy and four weeks of proton pump inhibitor therapy, H. pylori antigen was tested in stools.

A substantial correlation was noted between nausea, epigastric pain, and water brash with a p-value, 0.001. Similarly, the p-value was < 0.05 between bile reflux, hiatus hernia, and reflux and the p-value was < 0.001 among hiatus hernia and reflux. In the follow-up assessment, after triple therapy, H. pylori antigen tests were found to be negative in about 94% of the trial population, who were administered rabeprazole which displayed similarity to omeprazole-recipients (92%).

Both rabeprazole and omeprazole have comparable H. pylori elimination rates when co-administered with antibiotics like clarithromycin and amoxicillin for two weeks.